Latest News

Comtech Telecommunications (CMTL) has just posted Q2 2026 results that keep the focus squarely on profitability, with Q1 2026 revenue of US$111.0 million, a basic EPS loss of US$0.67, and net income loss of US$19.8 million. Over recent quarters the company has seen revenue move from US$115.8 million and an EPS loss of US$52.93 in Q1 2025 to US$130.4 million and an EPS loss of US$0.39 in Q4 2025, with net income losses shifting from US$155.9 million to US$11.6 million across the same period...

OCI (ENXTAM:OCI) FY 2025 earnings snapshot OCI (ENXTAM:OCI) has opened FY 2025 with a mixed first half, reporting total revenue of US$566.9 million and a basic EPS loss of US$1.57, alongside earnings from discontinued operations of US$673.6 million and net income loss excluding extra items of US$330.6 million, against a share price of €3.48. Over recent periods the company has seen revenue move from US$509 million in 1H 2024 to US$566.9 million in 1H 2025. Basic EPS shifted from a loss of...

Chair transition puts governance in focus for Great Eastern Holdings Great Eastern Holdings (SGX:G07) has drawn fresh attention after announcing that Chairman Soon Tit Koon will step down following the April 14, 2026 AGM, with Dr. Andrew Khoo set to assume the role. For investors, the planned handover signals continuity in board oversight while raising timely questions about how Dr. Khoo's regulatory and insurance sector experience might shape governance priorities and long term capital...

Monte Rosa Therapeutics (GLUE) just posted its FY 2025 third quarter numbers, with revenue of US$12.8 million and a basic EPS loss of US$0.33 off a net income loss of US$27.1 million, setting a clear snapshot of where the business stands today. Over recent periods, the company has seen revenue move from US$60.6 million in Q4 2024 to US$84.9 million in Q1 2025, then to US$23.2 million in Q2 2025 and US$12.8 million in Q3 2025. Over the same timeframe, basic EPS shifted from a profit of US$0.16...

On 12 March 2026, Swiss Life Holding AG reported full-year 2025 results showing net income of CHF 1,234 million and slightly higher earnings per share, while also announcing an annual dividend of CHF 36.50 per share payable on 13 May 2026. The combination of steady profit growth and a higher cash distribution offers fresh insight into how Swiss Life balances shareholder returns with capital needs. With Swiss Life pairing higher earnings per share and an increased CHF 36.50 dividend, we’ll...

In March 2026, Merck KGaA reported that its fourth-quarter 2025 sales slipped to €5,248.6 million and net income declined to €319.2 million, while full-year 2025 sales were broadly flat at €21.10 billion with net income of €2.61 billion, and it guided 2026 group net sales to €20–€21.10 billion, implying an organic sales change of about 1% decline to 2% growth. The company also proposed maintaining a stable €2.20 dividend at its April 24 Annual General Meeting, highlighting an emphasis on...

Embassy Bancorp (EMYB) has posted a clean set of Q3 2025 numbers, with total revenue of US$11.7 million and basic EPS of US$0.50, against a 12 month backdrop where revenue on a trailing basis moved from US$39.8 million to US$44.0 million and EPS from US$1.37 to US$1.68. The latest quarter sits within a year where earnings grew 21.3% versus the longer term trend and sets the stage for investors to focus on how a 29.1% net margin and a 2.58% net interest margin shape the quality and resilience...

Kaspi.kz (NasdaqGS:KSPI) has posted its FY 2025 results with Q4 revenue at KZT 1.1t and net income at KZT 276,983 million, translating into basic EPS of KZT 1,451.81, against a backdrop of trailing 12 month revenue of KZT 4.0t and net income of KZT 1,073,177 million. Over recent periods, the company has seen revenue move from KZT 744,178 million in Q4 2024 to KZT 1,146,548 million in Q4 2025, while quarterly basic EPS shifted from KZT 1,641.41 to KZT 1,451.81 and trailing basic EPS moved from...

Black Diamond Therapeutics (BDTX) just posted a sharp swing into profit for FY 2025, with first half revenue of US$70 million translating to basic EPS of US$0.81, compared with losses in both halves of FY 2024. Over the past year, the company has seen revenue move from US$0 to US$70 million while basic EPS has shifted from losses of US$0.71 and US$0.56 in FY 2024 to a trailing 12 month figure of US$0.25. This sets up a results season where investors will focus squarely on how durable these...

Springer Nature KGaA (XTRA:SPG) has reported solid headline numbers for FY 2025, with first half revenue of €969.9 million and basic EPS of €0.65. Trailing 12 month revenue stands at about €1.9 billion and EPS at €0.81, against a current share price of €16.98. The company has seen revenue increase from €940.5 million to €969.9 million between the first halves of 2024 and 2025, with basic EPS over the same period rising from €0.17 to €0.65. This places expanding net profit margins at the...

Stoke Therapeutics (STOK) has reported FY 2025 results that feature a wide range of quarterly outcomes. Q1 revenue was US$158.6 million with EPS of US$1.95, followed by Q2 revenue of US$13.8 million and an EPS loss of US$0.40, and Q3 revenue of US$10.6 million with an EPS loss of US$0.65. Over recent periods the company has seen revenue move between US$4.8 million and US$158.6 million per quarter, while EPS has shifted from a US$2.07 loss in FY 2024 to a US$1.95 profit and then back into...

WW International (WW) has just posted its FY 2025 results with Q3 revenue of US$172.1 million and a basic EPS loss of US$1.04, set against a trailing 12 month net income of about US$1.1 billion that reflects a large one off gain. Over recent quarters the company has seen revenue move between US$184.4 million and US$202.1 million, while EPS has swung from a profit of US$0.31 to a loss of US$0.91 and then a very large profit of US$15.71. This pattern points to margins that appear to be heavily...

Q3 2026 snapshot: Value Line (VALU) leans on margins as earnings trends soften Value Line (VALU) has just reported its Q3 2026 results, with recent quarters showing revenue around US$8.6 million and basic EPS between US$0.42 and US$0.69, while trailing twelve month EPS sits a little above US$2.25. Over the last six reported quarters, revenue has ranged from US$8.39 million to US$8.97 million and basic EPS has moved between US$0.42 and US$0.69, setting up a picture where high profitability...

Coya Therapeutics (COYA) has released its FY 2025 results, reporting fourth quarter revenue of US$4.0 million and a basic EPS loss of US$0.34, alongside trailing twelve month revenue of US$7.9 million and a basic EPS loss of US$1.27. The company’s revenue increased from US$0.00 million in the third quarter of 2024 to US$3.6 million in the third quarter of 2025, while quarterly basic EPS has ranged from a loss of US$0.44 in the first quarter of 2025 to a loss of US$0.13 in the third quarter of...

Zomedica (OTCPK:ZOMD.F) has reported its FY 2025 third quarter with total revenue of US$8.1 million and a basic EPS loss of US$0.006, alongside a net loss of US$6.1 million. Over recent quarters, revenue has moved from US$6.1 million in Q2 2024 to US$6.5 million in Q1 2025 and US$8.1 million in Q3 2025, while quarterly net losses have ranged from US$6.1 million to US$63.8 million and trailing twelve month revenue has reached US$29.5 million against a trailing net loss of US$84.5 million. For...

AGT Food and Ingredients FY 2025 Results Snapshot AGT Food and Ingredients (TSX:AGTF) has released a mixed FY 2025 update, reporting Q3 revenue of $654.2 million alongside a basic EPS loss of $0.62 and net income loss of $13.2 million, while trailing 12 month EPS is a loss of $0.46 on $3.2 billion of revenue. Over recent periods, the company’s quarterly revenue moved from $776.8 million in Q3 2024 to $1.0 billion in Q4 2024, then to $654.2 million in Q3 2025. EPS shifted from a $0.02 loss in...

Consolidated Water (CWCO) has put up another solid top line in FY 2025 so far, with Q3 revenue of about US$35.1 million and basic EPS of roughly US$0.35, while the latest trailing twelve months show revenue of about US$130.8 million and EPS of around US$1.09. Over recent periods the company has seen revenue move from roughly US$28.4 million in Q4 2024 to US$35.1 million in Q3 2025, with quarterly EPS shifting from about US$0.11 to US$0.35 over the same stretch. This sets up a story where...

The FDA approved an updated label for Krystal Biotech's Vyjuvek (beremagene geperpavec svdt) for epidermolysis bullosa. KB803 progressed as an emerging therapy candidate in Krystal Biotech's pipeline. These developments affect the treatment options available for epidermolysis bullosa and the outlook for NasdaqGS:KRYS. Krystal Biotech, listed on NasdaqGS:KRYS, focuses on gene therapies for rare skin conditions such as epidermolysis bullosa. With Vyjuvek already in the market and KB803 moving...

Bumble (BMBL) has wrapped up FY 2025 with fourth quarter revenue of US$224.2 million and a basic EPS loss of US$4.06, alongside a net income loss of US$499.4 million. Over recent periods the company has seen quarterly revenue move from US$261.6 million in Q4 2024 to US$247.1 million in Q1 2025, US$248.2 million in Q2, US$246.2 million in Q3, and US$224.2 million in Q4. EPS swung between a profit of US$0.34 in Q3 and losses such as US$2.45 in Q2 and US$4.06 in Q4, setting up a story that is as...

Summit Midstream (SMC) has reported third quarter FY 2025 revenue of US$138.0 million with a basic EPS loss of US$0.13, as continued losses keep profitability in focus for investors. The company has seen revenue move from US$93.2 million in Q2 FY 2024 to US$138.0 million in Q3 FY 2025, while basic EPS over the same stretch has ranged from a loss of US$19.25 per share in Q3 FY 2024 to a loss of US$0.13 per share in the latest quarter, keeping margins firmly in the red and the quality of the...

Latest FY 2025 earnings snapshot Security National Financial (SNFC.A) closed FY 2025 with fourth quarter revenue of US$83.0 million and basic EPS of US$0.55, alongside trailing 12 month figures of US$344.6 million in revenue and EPS of US$1.30 that sit against earnings growth of 21.2% over the past year. Over recent periods, revenue has moved from US$79.3 million and EPS of effectively zero in Q4 2024 to US$83.0 million and EPS of US$0.55 in Q4 2025. Trailing net income reached US$32.2...

Julius Bär Gruppe (SWX:BAER) has posted its FY 2025 results with second half revenue of CHF 1,950.2 million and basic EPS of CHF 2.28, while trailing twelve month revenue came in at CHF 3,760.4 million and EPS at CHF 3.72. Over recent periods the bank has seen revenue move from CHF 1,916.3 million in the second half of 2024 to CHF 1,810.2 million in the first half of 2025 and then to CHF 1,950.2 million in the latest half, alongside EPS shifting from CHF 2.78 to CHF 1.44 and then CHF 2.28...

Vireo Growth (CNSX:VREO) has released its FY 2025 numbers, reporting third quarter revenue of US$91.7 million and a basic EPS loss of US$0.03, alongside a trailing twelve month loss of US$63.4 million on revenue of US$189.3 million. Over recent quarters the company’s revenue moved from US$25.2 million in Q2 2024 to US$25.0 million in Q4 2024, then to US$24.5 million, US$48.1 million and US$91.7 million across Q1 to Q3 2025. Quarterly basic EPS remained in loss-making territory between roughly...

Silvercrest Asset Management Group (SAMG) has reported third quarter FY 2025 revenue of US$31.3 million and basic EPS of US$0.07, with trailing 12 month revenue at US$125.3 million and EPS at US$0.73 providing the broader earnings backdrop. Over recent periods, revenue has moved between US$30.4 million and US$31.4 million per quarter, while quarterly EPS has ranged from US$0.07 to US$0.28. This gives investors a clearer view of how the income statement has evolved into the current trailing 12...